Who We Are
Remedy Pharmaceuticals’ unwavering commitment is to help people afflicted with central nervous system (CNS) related diseases and injuries to not only survive, but to live life to the fullest.
In May of 2017, Biogen [NASDAQ:BIIB] acquired our phase 3-ready novel drug, CIRARA®. The transaction was the culmination of a dozen-year determined effort to address a large unmet medical need – cerebral edema in large hemispheric infarction (LHI), a deadly form of stroke with a mortality rate of up to 80%.
While the Biogen deal closed one chapter in Remedy’s history, another opened as we pursue new innovative therapies in other still-vexing CNS-related areas, because we know people in need are counting on us to find answers.
UNCONVENTIONAL THINKING AT WORK
In May of 2017, Biogen [NASDAQ:BIIB] acquired our phase 3-ready novel drug, CIRARA®. The transaction was the culmination of a dozen-year determined effort to address a large unmet medical need – cerebral edema in large hemispheric infarction (LHI), a deadly form of stroke with a mortality rate of up to 80%.
While the Biogen deal closed one chapter in Remedy’s history, another opened as we pursue new innovative therapies in other still-vexing CNS-related areas, because we know people in need are counting on us to find answers.
UNCONVENTIONAL THINKING AT WORK